Illustrated treatment of refractory immune thrombotic thrombocytopenic purpura with caplacizumab

BMJ Case Rep. 2021 Aug 9;14(8):e245600. doi: 10.1136/bcr-2021-245600.

Authors

Brandon Tse¹, Megan Buchholz², Katerina Pavenski^{3

4}

Affiliations

¹ Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
² Apheresis Unit, St Michael's Hospital, Toronto, Ontario, Canada.
³ Departments of Laboratory Medicine and Medicine, St Michael's Hospital- Unity Health Toronto, Toronto, Ontario, Canada katerina.pavenski@unityhealth.to.
⁴ Departments of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.

No abstract available

Keywords: haematology (incl blood transfusion); thrombotic thrombocytopenic purpura.

Publication types

Case Reports

MeSH terms

ADAMTS13 Protein
Humans
Plasma Exchange
Purpura, Thrombotic Thrombocytopenic* / drug therapy
Single-Domain Antibodies*

Substances

Single-Domain Antibodies
caplacizumab
ADAMTS13 Protein